Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia

Barnett PG, Scott JY, Krystal JH, Rosenheck RA

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
22697193

DOI
10.4088/JCP.11m07070

Original Paper URL
http://article.psychiatrist.com/dao_1-login.asp?ID=10007874&RSID=54764774725668

Indexing Status
Subject indexing assigned by NLM

MeSH
Antipsychotic Agents /economics /therapeutic use; Comparative Effectiveness Research; Cost-Benefit Analysis; Delayed-Action Preparations; Double-Blind Method; Drug Costs; Female; Health Care Costs; Hospitalization /economics /statistics & numerical data; Humans; Injections; Kaplan-Meier Estimate; Male; Middle Aged; Models, Econometric; Psychotic Disorders /drug therapy; Risperidone /economics /therapeutic use; Schizophrenia /drug therapy; United States; Veterans

AccessionNumber
22012024012

Date bibliographic record published
08/01/2013